The Center for Biosimilars® recaps the top news for the week of December 17, 2018.
Transcript:
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of December 17.
Number 5: A real-world study has underscored the safety and effectiveness of Celltrion’s infliximab biosimilar, CT-P13, in patients with Crohn disease.
Number 4: A district court in Pennsylvania recently denied Johnson and Johnsons motion to dismiss the antitrust claim brought against the company by Walgreen and Kroger in regard to sales of J&J’s reference infliximab product, Remicade.
Number 3: Last week, insurer Cigna and pharmacy benefit manager Express Scripts overcame 2 hurdles to completing their 67-billion-dollar merger as New York and California insurance regulators signed off on the deal.
Number 2: Pfizer recently announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion of its proposed bevacizumab biosimilar.
Number 1: The FDA approved Celltrion and Teva’s biosimilar trastuzumab, Herzuma, for the treatment of HER2-positive breast cancer.
Finally, last week, our e-newsletter asked if the United States should rein in the number of patents it grants to drugs.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.